Cargando…
mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Diabetic cardiomyopathy is a critical diabetes-mediated co-morbidity characterized by cardiac dysfunction and heart failure, without predisposing hypertensive or atherosclerotic conditions. Metabolic insulin resistance, promoting hyperglycemia and hyperlipidemia, is the primary cause of diabetes-rel...
Autores principales: | Saha, Sumit, Fang, Xianjun, Green, Christopher D., Das, Anindita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606418/ https://www.ncbi.nlm.nih.gov/pubmed/37894760 http://dx.doi.org/10.3390/ijms242015078 |
Ejemplares similares
-
SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes
por: Schaub, Jennifer A., et al.
Publicado: (2023) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
por: Walters, Hannah E., et al.
Publicado: (2018) -
Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors
por: Kogot-Levin, Aviram, et al.
Publicado: (2020) -
LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018)